A detailed history of Armistice Capital, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 49,915 shares of MDGL stock, worth $15.9 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
49,915
Previous 150,000 66.72%
Holding current value
$15.9 Million
Previous $42 Million 74.8%
% of portfolio
0.18%
Previous 0.55%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$212.22 - $292.96 $21.2 Million - $29.3 Million
-100,085 Reduced 66.72%
49,915 $10.6 Million
Q2 2024

Aug 14, 2024

SELL
$193.33 - $291.99 $3.48 Million - $5.26 Million
-18,000 Reduced 10.71%
150,000 $42 Million
Q1 2024

May 15, 2024

BUY
$171.37 - $283.23 $20.2 Million - $33.4 Million
118,000 Added 236.0%
168,000 $44.9 Million
Q4 2023

Feb 13, 2024

SELL
$120.4 - $237.13 $6.98 Million - $13.8 Million
-58,000 Reduced 53.7%
50,000 $11.6 Million
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $4.09 Million - $6.32 Million
-28,000 Reduced 20.59%
108,000 $15.8 Million
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $28.5 Million - $43.7 Million
-140,000 Reduced 50.72%
136,000 $31.4 Million
Q1 2023

May 15, 2023

BUY
$231.06 - $307.08 $15.7 Million - $20.9 Million
68,000 Added 32.69%
276,000 $66.9 Million
Q4 2022

Feb 14, 2023

SELL
$58.39 - $296.54 $60 Million - $305 Million
-1,028,000 Reduced 83.17%
208,000 $60.4 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $8.24 Million - $10.8 Million
136,000 Added 12.36%
1,236,000 $80.3 Million
Q2 2022

Aug 15, 2022

BUY
$58.04 - $100.2 $7.08 Million - $12.2 Million
122,000 Added 12.47%
1,100,000 $78.7 Million
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $8.16 Million - $14.9 Million
-146,000 Reduced 12.99%
978,000 $96 Million
Q4 2021

Feb 14, 2022

BUY
$72.34 - $95.09 $6.37 Million - $8.37 Million
88,000 Added 8.49%
1,124,000 $95.2 Million
Q3 2021

Nov 15, 2021

BUY
$78.35 - $105.02 $34.8 Million - $46.6 Million
444,000 Added 75.0%
1,036,000 $82.7 Million
Q2 2021

Aug 16, 2021

BUY
$97.2 - $137.59 $23.5 Million - $33.3 Million
242,000 Added 69.14%
592,000 $57.7 Million
Q1 2021

May 17, 2021

BUY
$108.54 - $125.2 $3.69 Million - $4.26 Million
34,000 Added 10.76%
350,000 $40.9 Million
Q4 2020

Feb 16, 2021

BUY
$110.06 - $133.7 $4.18 Million - $5.08 Million
38,000 Added 13.67%
316,000 $35.1 Million
Q3 2020

Nov 16, 2020

BUY
$99.78 - $124.21 $2.99 Million - $3.73 Million
30,000 Added 12.1%
278,000 $33 Million
Q2 2020

Aug 14, 2020

BUY
$60.13 - $125.71 $1.92 Million - $4.02 Million
32,000 Added 14.81%
248,000 $28.1 Million
Q1 2020

May 15, 2020

BUY
$66.76 - $93.49 $3.74 Million - $5.24 Million
56,000 Added 35.0%
216,000 $14.4 Million
Q4 2019

Feb 14, 2020

BUY
$84.28 - $118.5 $4.38 Million - $6.16 Million
52,000 Added 48.15%
160,000 $14.6 Million
Q3 2019

Nov 14, 2019

SELL
$84.4 - $106.53 $25.3 Million - $32 Million
-300,000 Reduced 73.53%
108,000 $9.31 Million
Q2 2019

Aug 14, 2019

SELL
$91.13 - $142.5 $1.55 Million - $2.42 Million
-17,000 Reduced 4.0%
408,000 $42.8 Million
Q1 2019

May 15, 2019

BUY
$103.48 - $143.84 $44 Million - $61.1 Million
425,000 New
425,000 $53.2 Million
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $7.58 Million - $17.2 Million
-80,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $16.6 Million - $24 Million
80,000 New
80,000 $17.1 Million
Q2 2018

Aug 14, 2018

SELL
$101.55 - $313.9 $10.4 Million - $32 Million
-102,000 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $3.92 Million - $6.26 Million
42,000 Added 70.0%
102,000 $11.9 Million
Q4 2017

Feb 14, 2018

SELL
$39.35 - $97.37 $5.98 Million - $14.8 Million
-152,000 Reduced 71.7%
60,000 $5.51 Million
Q3 2017

Nov 14, 2017

BUY
$15.48 - $46.19 $3.28 Million - $9.79 Million
212,000
212,000 $9.54 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.45B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.